| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human protein was used as the immunogen for the Migfilin-1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Migfilin-1 Antibody / FBLIM1 / Filamin B is an antibody targeting Migfilin-1. Host: Rabbit. Monoclonal. Clone: FBLIM1/8189R. Format: Purified. Applications: IHC-P.
Key elements and design rationale
- Target: Migfilin-1.
- Immunogen: Recombinant full-length human protein was used as the immunogen for the Migfilin-1 antibody..
- Species reactivity: Human.
- Localization: Cytoplasm.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
FBLIM1 (also known as Filamin B, MIG-2 Interacting Protein and Migfilin) is an important component of cell-extracellular matrix adhesion. Kindlin-2 binds integrins and is involved in ECM adhesion, actin assembly and cell shape modulation.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
